andexanet

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
051020142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
INTRODUCTION Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Essentials There is currently no approved reversal agent for factor Xa (FXa) inhibitors Andexanet alfa has been developed to… (More)
Is this relevant?
2017
2017
Direct factor Xa (FXa) inhibitors lack a specific reversal agent for emergencies such as major bleeding or urgent surgery… (More)
Is this relevant?
Review
2017
Review
2017
Activated coagulation factor X (FXa) is a common target for classic and newer anticoagulants. Parenteral anticoagulants with an… (More)
Is this relevant?
2017
2017
 
Is this relevant?
Review
2017
Review
2017
Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared to vitamin K antagonists (VKAs) for… (More)
Is this relevant?
2016
2016
Despite direct oral anticoagulants becoming a mainstay of anticoagulant therapy, the effective, timely, and safe reversal of… (More)
Is this relevant?
2016
2016
The need for oral anticoagulation is rising to combat an increasing prevalence of atrial fibrillation and venous thromboembolism… (More)
Is this relevant?
Review
2016
Review
2016
Since affecting hemostasis, all the anticoagulant drugs carry a risk of bleeding. Minor bleeds may be managed without the need to… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?